Michael Erb
@Michael_A_Erb
Followers
2K
Following
869
Media
42
Statuses
688
Associate Professor @scrippsresearch. Chemical biology and gene regulation.
Joined May 2016
We keep stumbling on molecular glues, but how can they be made for a pre-selected target? We’ve been working on this question, envisioning a high-throughput chemistry (HTC)-based approach to convert pre-existing ligands into molecular glues.
3
29
193
Yesterday's intractable targets session was a great success thanks to lively talks from @DanNomura and @xzhang85. Big thanks to CICR for putting together some really great topics.
Not sure what @Michael_A_Erb did to Elon but my tweet about his excellent talk at #AACR25 got ZERO views. Michael’s science is way too interesting to leave it at this. Second try with some pics from his talk about identifying molecular degraders targeting ENL.
0
2
29
RT @HartungIngo: The educational day at #AACR25 was again well-invested time thanks to the program committee selecting highly relevant topi….
0
12
0
Hope to see many of you for Part 3 of the "Chemistry to the Clinic" series today at 2:30p!.
Wonderful to be back in Chicago for #2025AACR! I’ll be giving a talk on our latest work tomorrow in the Educational Session on Advances in Ligand Discovery to Enable Previously Intractable Targets on Sat Apr 26th 2:30-4:00pm in S406 McCormick South alongside @Michael_A_Erb &
1
0
11
Check out this very cool extension of our work from the Bollong Group!.
A 2-for-1 resistance mechanism! Inspired by our colleague @Michael_A_Erb, @KaylaENutsch demonstrates that increased levels of acyl-CoAs not only promote resistance to active site HAT inhibitors but TEAD inhibitors as well.
0
0
11
RT @BogerLab: Insights into Free Drug Release from Efficacious N-Acyl O-Aminophenol Duocarmycin Prodrugs | ACS Chemical Biology https://t.c….
0
6
0
RT @jaybradner: The juice is worth the squeeze. Elegant use of dTAG to model KRAS degradation in vivo, for therapeutic hypothesis validatio….
0
4
0
Really enjoyed this session and conference, thanks AACR for hosting a great program!.
Mikko Taipale, Michael A. Erb, and Xin Zhou discussed "Emerging Frontiers in Bivalent Degraders" in a special #AACRCICR-organized session at the AACR Conference on Optimizing Therapeutic Efficacy and Tolerability through Cancer Chemistry. #AACRchem24 @mike_tilapia @Michael_A_Erb
0
0
10
Thanks for chairing a great session Katherine, this was too much fun!.
I really enjoyed chairing the #AACRCICR session today focused on bivalent degraders. Thank you to @Michael_A_Erb, @mike_tilapia , and @xinzhoulab for the beautiful talks! #AACRchem24
0
0
14
After a half-day at school, my eldest just bumped into Reza Ghadiri, @BogerLab, and Ben Cravatt within the space of 5 min. His chemical education is complete.
4
1
39
RT @StephanHacker2: Interesting paper by the group of @MichaelBollong of @scrippsresearch in @J_A_C_S. A high-throughput assay for cysteine….
0
5
0
RT @DanNomura: New cysteine warhead from @MichaelBollong lab @scrippsresearch : Scalable Thiol Reactivity Profiling Identifies Azetidin….
0
10
0
Check out this thoughtful Preview from Billy on our recent manuscript in Molecular Cell. Thanks Billy!.
Pioneer TFs have long been considered "undruggable" 💊 🧬 However, @scrippsresearch teams led by Ben Cravatt and @Michael_A_Erb have elegantly developed a first-in-class ligand for the pioneer TF FOXA1. In @MolecularCell, we commented on this groundbreaking work:
1
4
41
RT @GhayasIssa: The first BTC trial to target AML MRD with combination of menin and BCL2 inhibition is now open! Huge team effort and more….
0
12
0
Go Dodgers!.
1
0
4
RT @alessiociulli: Nice writeup in @nchembio of key themes in the science covered at our Symposium celebrating the opening of Dundee’s Ce….
0
12
0
RT @AACR: Emerging Frontiers in Bivalent Degraders:.Mikko Taipale, Riccardo Sabatini, and @Michael_A_Erb will address this topic at the AAC….
0
1
0
RT @Curebound_OFCL: Curebound is growing. We're looking for experienced, creative professionals with strong work ethic and a passion for fi….
0
1
0